Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-31
2009-12-15
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S283000, C546S196000, C548S579000, C548S950000
Reexamination Certificate
active
07632840
ABSTRACT:
A quinazoline derivative of the formula I:wherein: R1, R2, R3, R3a, R4, R5, R5aR6, R7, a, m and p are as defined in the description. Also claimed are pharmaceutical compositions containing the quinazoline derivative, the use of the quinazoline derivatives as medicaments and processes for the preparation of the quinazoline derivative. The quinazoline derivatives of formula I, are useful in the treatment of hyperproliferative disorders such as a cancer.
REFERENCES:
patent: 4335127 (1982-06-01), Vandenberk et al.
patent: 4921863 (1990-05-01), Sugimoto et al.
patent: 5457105 (1995-10-01), Barker
patent: 5616582 (1997-04-01), Barker
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5770599 (1998-06-01), Gibson
patent: 6297258 (2001-10-01), Wissner et al.
patent: 6562319 (2003-05-01), Mishani et al.
patent: 6617329 (2003-09-01), Himmelsbach et al.
patent: 6972288 (2005-12-01), Himmelsbach et al.
patent: 7148230 (2006-12-01), Bradbury et al.
patent: 2002/0049197 (2002-04-01), Himmelsbach et al.
patent: 2002/0082270 (2002-06-01), Himmelsbach et al.
patent: 2002/0128553 (2002-09-01), Mishani et al.
patent: 2002/0169180 (2002-11-01), Himmelsbach et al.
patent: 2002/0177601 (2002-11-01), Himmelsbach et al.
patent: 2004/0048880 (2004-03-01), Himmelsbach et al.
patent: 2004/0176361 (2004-09-01), Fujio et al.
patent: 2005/0043336 (2005-02-01), Hennequin et al.
patent: 2005/0054662 (2005-03-01), Hennequin et al.
patent: 2005/0165035 (2005-07-01), Bradbury et al.
patent: 2005/0215574 (2005-09-01), Bradbury et al.
patent: 2006/0211714 (2006-09-01), Hennequin et al.
patent: 2006/0287295 (2006-12-01), Barlaam et al.
patent: 2007/0015743 (2007-01-01), Bradbury et al.
patent: 2007/0032508 (2007-02-01), Bradbury et al.
patent: 2007/0032513 (2007-02-01), Hennequin et al.
patent: 2007/0037837 (2007-02-01), Hennequin et al.
patent: 2007/0043009 (2007-02-01), Hennequin et al.
patent: 2007/0043010 (2007-02-01), Bradbury et al.
patent: 2007/0082921 (2007-04-01), Hennequin et al.
patent: 2007/0088044 (2007-04-01), Hennequin et al.
patent: 2007/0099943 (2007-05-01), Bradbury et al.
patent: 2007/0149546 (2007-06-01), Bradbury et al.
patent: 2007/0232607 (2007-10-01), Bradbury et al.
patent: 2007/0244136 (2007-10-01), Hennequin et al.
patent: 10040527 (2002-02-01), None
patent: 0 288 563 (1994-05-01), None
patent: 0 566 226 (1995-11-01), None
patent: 0 837 063 (1998-04-01), None
patent: 1 230 919 (2002-08-01), None
patent: 1 369 418 (2003-12-01), None
patent: WO 88/02365 (1988-04-01), None
patent: WO 96/09294 (1996-03-01), None
patent: WO 96/30347 (1996-10-01), None
patent: WO 96/33977 (1996-10-01), None
patent: WO 96/33978 (1996-10-01), None
patent: WO 96/33979 (1996-10-01), None
patent: WO 96/33980 (1996-10-01), None
patent: WO 96/33981 (1996-10-01), None
patent: WO 96/39145 (1996-12-01), None
patent: WO 97/03069 (1997-01-01), None
patent: WO 97/30034 (1997-08-01), None
patent: WO 97/30035 (1997-08-01), None
patent: WO 97/38983 (1997-10-01), None
patent: WO 97/38994 (1997-10-01), None
patent: WO 98/02434 (1998-01-01), None
patent: WO 98/13354 (1998-04-01), None
patent: WO 99/06378 (1999-02-01), None
patent: WO 99/35132 (1999-07-01), None
patent: WO 00/09481 (2000-02-01), None
patent: WO 00/18740 (2000-04-01), None
patent: WO 00/20402 (2000-04-01), None
patent: WO 00/20402 (2000-04-01), None
patent: WO 00/24718 (2000-05-01), None
patent: WO 00/44728 (2000-08-01), None
patent: WO 00/51991 (2000-09-01), None
patent: WO 00/55141 (2000-09-01), None
patent: WO 00/56720 (2000-09-01), None
patent: WO 00/78735 (2000-12-01), None
patent: WO 01/04102 (2001-01-01), None
patent: WO 01/07432 (2001-02-01), None
patent: WO 01/21596 (2001-03-01), None
patent: WO 01/21597 (2001-03-01), None
patent: WO 01/32651 (2001-05-01), None
patent: WO 01/66099 (2001-09-01), None
patent: WO 01/94341 (2001-12-01), None
patent: WO 01/98277 (2001-12-01), None
patent: WO 02/02534 (2002-01-01), None
patent: WO 02/08224 (2002-01-01), None
patent: WO 02/16352 (2002-02-01), None
patent: WO 02/18372 (2002-03-01), None
patent: WO 02/24684 (2002-03-01), None
patent: WO 02/30924 (2002-04-01), None
patent: WO 02/34744 (2002-05-01), None
patent: WO 02/41882 (2002-05-01), None
patent: WO 02/44166 (2002-06-01), None
patent: WO 02/48117 (2002-06-01), None
patent: WO 02/056882 (2002-07-01), None
patent: WO 02/062767 (2002-08-01), None
patent: WO 02/066445 (2002-08-01), None
patent: WO 02/068409 (2002-09-01), None
patent: WO 02/073235 (2002-09-01), None
patent: WO 02/076976 (2002-10-01), None
patent: WO 02/092577 (2002-11-01), None
patent: WO 02/092578 (2002-11-01), None
patent: WO 02/097490 (2002-12-01), None
patent: WO 03/040108 (2003-05-01), None
patent: WO 03/040109 (2003-05-01), None
patent: WO 03/049740 (2003-06-01), None
patent: WO 03/082290 (2003-10-01), None
patent: WO 03/082831 (2003-10-01), None
patent: WO 2004/064718 (2004-08-01), None
patent: WO 2004/093880 (2004-11-01), None
patent: WO 2004/096226 (2004-11-01), None
patent: WO 2005/012290 (2005-02-01), None
patent: WO 2005/013998 (2005-02-01), None
patent: WO 2005/026150 (2005-03-01), None
patent: WO 2005/026151 (2005-03-01), None
patent: WO 2005/026152 (2005-03-01), None
patent: WO 2005/026156 (2005-03-01), None
patent: WO 2005/026157 (2005-03-01), None
patent: WO 2005/028469 (2005-03-01), None
patent: WO 2005/028470 (2005-03-01), None
patent: WO 2005/030757 (2005-04-01), None
patent: WO 2005/030765 (2005-04-01), None
patent: WO 2005/051923 (2005-06-01), None
patent: WO 2005/118572 (2005-12-01), None
patent: WO 2006/064196 (2006-06-01), None
patent: WO 2006/090163 (2006-08-01), None
patent: WO 2006/092573 (2006-09-01), None
patent: WO 2006/092574 (2006-09-01), None
patent: WO 2006/117521 (2006-11-01), None
patent: WO 2006/117523 (2006-11-01), None
patent: WO 2007/034143 (2007-03-01), None
patent: WO 2007/034144 (2007-03-01), None
patent: WO 2007/063291 (2007-06-01), None
patent: WO 2007/063293 (2007-06-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, p. 205.
DörwaId, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Tsou, H-R, et al., “6-Substituted-4-(3-Bromophenylamino) Quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity”, Journal of Medicinal Chemistry, American Chemical Society, US, vol. 44, No. 17, 2001 , pp. 2719-2734.
A. Vema, et al., “Design of EGFR Kinase Inhibitors: A Ligand-Based Approach and Its Confirmation with Structure-Based Studies”, Bioorg. Med. Chem., vol. 11, 2003, pp. 4643-4653.
Hennequin et al. “Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors” Bioorganic & Medicinal Chemistry Letters 16: 2672-2676 (2006).
Stamos et al. “Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor” J. Biol. Chem. 277(48):46265-46272 (2002).
Traxler et al. “Protein tyrosine kinase inhibitors in cancer treatment” Exp. Opin. Ther. Patents 7(6):571-588 (1997).
Traxler et al. “Tyrosine kinase inhibitors in cancer treatment (Part II)” Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).
Tsou et al. “6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity” J. Med. Chem. 44:2719-2734 (2001).
Vema et al. “Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies” Bioorg Med Chem. 11(21):4643-4653 (2003).
Ballard et al. “Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket” Bioorg Med Chem Lett.
Delouvrie Benedicte
Halsall Christopher Thomas
Harris Craig Steven
Hennequin Laurent Francois Andre
Pease Janet Elizabeth
AstraZeneca AB
Morgan & Lewis & Bockius, LLP
Willis Douglas M
Wilson James O
LandOfFree
Quinazoline compounds for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazoline compounds for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline compounds for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4138106